The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
An agreement with such a big name. Considering the low level of the SP yesterday (on a 5-year chart) I would have thought that a 90% rise was more appropriate, and to the point. Such a weak market this, on AIM, for responding to good news....
Look at Toronto stock Pulsar since 29.2.24, from 0.55$ to 1.59$, that's 189% up! Maybe good helium news at HE1 ought to be rewarded more, similar to what's happened with plsr. Go here to see plsr's price chart and newsflow: Https://shorturl.at/lCNY6
Tightening uranium market
Https://www.youtube.com/watch?app=desktop&v=BLcqLe55twc
when does neo start to reflect this?
I decided to sell the lot. Got burnt with IOG this Autumn, can't risk that (administration) happening again. Also this Board doesn't seem to have a clue about solving this, or - as many have suggested - want this demise to occur and then reappear in some other guise.
jason saying grow umr to 20, 30 or 40p/share. seems to me that the no. of near-production assets identified in east and south africa (by *****on & jason) are probably too numerous for maru and ska to take, as portfolio projects, and that's why imo they need a third vehicle like umr, with the advantage of a main market listing (not aim).
https://audioboom.com/posts/8416396-midweek-takeaway-with-jason-brewer-executive-director-of-unicorn-mineral-resources-lse-umr
Like many on AIM they did a (very) low-price placing. The plus side is that the funding is secure for a longer period into the future. That gives a sounder base, going forward. So let's revisit that buy territory of above 50p ;-)
Broader field mentioned: Other pre-clinical studies have been conducted that demonstrate that oral gallium maltolate may prove to be a viable treatment alternative across multiple solid tumors as well